Key result
Intraoperative photodynamic therapy was feasible and safe in 10 patients with recurrent retroperitoneal sarcomas, with 2 patients remaining recurrence-free at 24 and 28 months.
Why the study?
Is intraoperative photodynamic therapy feasible and safe in patients with recurrent retroperitoneal sarcomas?
Is intraoperative photodynamic therapy feasible and safe in patients with recurrent retroperitoneal sarcomas?
Intraoperative photodynamic therapy is a feasible adjuvant treatment for recurrent retroperitoneal sarcomas, though further evaluation of effectiveness is needed.
Answers are grounded in this paper and cite their sources.
Adjuvant PDT feasible after resection in recurrent retroperitoneal sarcomas; leaves open efficacy and warrants prospective trials.
A pilot study was done to determine the feasibility of adjuvant photodynamic therapy (PDT) in recurrent retroperitoneal sarcomas. Ten patients, who had recurrences after conventional methods of treatment, had repeated resections of the tumor and intraoperative photodynamic treatment to the tumor bed. The methods and equipment used are detailed. In eight of ten patients, a complete resection was possible, and two patients are alive without recurrence at 28 and 24 months. There were no complications from the therapy. Tumors elicited red fluorescence, which helped in identifying residual tumor areas. Adjuvant PDT is a feasible alternative although its effectiveness should be evaluated further.
No takes yet. Share an insight, caveat, or question.
Nambisan et al. (1988) studied recurrent retroperitoneal sarcomas (n=10). Intraoperative photodynamic therapy (PDT) was evaluated on Feasibility and recurrence. Intraoperative photodynamic therapy was feasible and safe in 10 patients with recurrent retroperitoneal sarcomas, with 2 patients remaining recurrence-free at 24 and 28 months.
Synapse has enriched 10 related papers. Consider them for comparative context: